{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Product+F",
    "query": {
      "intervention": "Product F"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 397,
    "total_pages": 40,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Product+F&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T01:17:01.723Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00934089",
      "title": "A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "PF-04217329",
          "type": "DRUG"
        },
        {
          "name": "latanoprost vehicle",
          "type": "DRUG"
        },
        {
          "name": "latanoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 31,
      "start_date": "2010-01",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-03",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 8,
      "location_summary": "Cypress, California • Garden Grove, California • Gardena, California + 4 more",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00934089"
    },
    {
      "nct_id": "NCT05284760",
      "title": "A Study of Soticlestat Tablets in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Soticlestat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2022-03-11",
      "completion_date": "2022-06-02",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05284760"
    },
    {
      "nct_id": "NCT02166463",
      "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ann Arbor Stage IIB Hodgkin Lymphoma",
        "Ann Arbor Stage IIIB Hodgkin Lymphoma",
        "Ann Arbor Stage IVA Hodgkin Lymphoma",
        "Ann Arbor Stage IVB Hodgkin Lymphoma",
        "Childhood Hodgkin Lymphoma",
        "Classic Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bleomycin Sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "2 Years to 22 Years"
      },
      "enrollment_count": 600,
      "start_date": "2015-03-19",
      "completion_date": "2026-10-03",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 182,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166463"
    },
    {
      "nct_id": "NCT03113500",
      "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult T-Cell Leukemia/Lymphoma",
        "Anaplastic Large Cell Lymphoma, ALK-Negative",
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Angioimmunoblastic T-Cell Lymphoma",
        "Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma",
        "Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma",
        "Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Hepatosplenic T-Cell Lymphoma",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2017-05-25",
      "completion_date": "2027-04-25",
      "has_results": true,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Hackensack, New Jersey • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03113500"
    },
    {
      "nct_id": "NCT06414798",
      "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Drug: ABBV-1088",
          "type": "DRUG"
        },
        {
          "name": "Drug: Placebo for ABBV-1088",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-05-13",
      "completion_date": "2025-02-08",
      "has_results": false,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06414798"
    },
    {
      "nct_id": "NCT07476144",
      "title": "Nicotine Pouch Pharmacokinetics Abuse Liability",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smoking Behaviors"
      ],
      "interventions": [
        {
          "name": "Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "JT International SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 55,
      "start_date": "2026-01-08",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 2,
      "location_summary": "Knoxville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07476144"
    },
    {
      "nct_id": "NCT00868309",
      "title": "A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Snake Bite",
        "Blood Coagulation Disorders"
      ],
      "interventions": [
        {
          "name": "Anavip",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CroFab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Instituto Bioclon S.A. de C.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-01",
      "completion_date": "2007-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-18",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00868309"
    },
    {
      "nct_id": "NCT00477412",
      "title": "Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 107,
      "start_date": "2007-04-03",
      "completion_date": "2020-10-28",
      "has_results": true,
      "last_update_posted_date": "2022-01-28",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00477412"
    },
    {
      "nct_id": "NCT01968551",
      "title": "Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1",
        "HIV Infections",
        "Acquired Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "DRV",
          "type": "DRUG"
        },
        {
          "name": "Baseline DRV- containing ARV regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2013-09-03",
      "completion_date": "2016-07-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968551"
    },
    {
      "nct_id": "NCT05894577",
      "title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Montelukast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Susanna Naggie, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 1453,
      "start_date": "2023-01-27",
      "completion_date": "2024-01-01",
      "has_results": true,
      "last_update_posted_date": "2025-01-17",
      "last_synced_at": "2026-09-03T01:17:01.723Z",
      "location_count": 109,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05894577"
    }
  ]
}